Literature DB >> 28444781

Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer's disease.

C A Budgeon1,2, K Murray3, B A Turlach1, S Baker4, V L Villemagne5,6, S C Burnham2.   

Abstract

In epidemiology, cohort studies utilised to monitor and assess disease status and progression often result in short-term and sparse follow-up data. Thus, gaining an understanding of the full-term disease pathogenesis can be difficult, requiring shorter-term data from many individuals to be collated. We investigate and evaluate methods to construct and quantify the underlying long-term longitudinal trajectories for disease markers using short-term follow-up data, specifically applied to Alzheimer's disease. We generate individuals' follow-up data to investigate approaches to this problem adopting a four-step modelling approach that (i) determines individual slopes and anchor points for their short-term trajectory, (ii) fits polynomials to these slopes and anchor points, (iii) integrates the reciprocated polynomials and (iv) inverts the resulting curve providing an estimate of the underlying longitudinal trajectory. To alleviate the potential problem of roots of polynomials falling into the region over which we integrate, we propose the use of non-negative polynomials in Step 2. We demonstrate that our approach can construct underlying sigmoidal trajectories from individuals' sparse, short-term follow-up data. Furthermore, to determine an optimal methodology, we consider variations to our modelling approach including contrasting linear mixed effects regression to linear regression in Step 1 and investigating different orders of polynomials in Step 2. Cubic order polynomials provided more accurate results, and there were negligible differences between regression methodologies. We use bootstrap confidence intervals to quantify the variability in our estimates of the underlying longitudinal trajectory and apply these methods to data from the Alzheimer's Disease Neuroimaging Initiative to demonstrate their practical use.
Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Alzheimer's disease; longitudinal trajectories; sigmoidal curves

Mesh:

Year:  2017        PMID: 28444781     DOI: 10.1002/sim.7300

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer's disease.

Authors:  Michael Vacher; Vincent Doré; Tenielle Porter; Lidija Milicic; Victor L Villemagne; Pierrick Bourgeat; Sam C Burnham; Timothy Cox; Colin L Masters; Christopher C Rowe; Jurgen Fripp; James D Doecke; Simon M Laws
Journal:  BMC Genomics       Date:  2022-05-26       Impact factor: 4.547

2.  Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition.

Authors:  Samantha C Burnham; Simon M Laws; Charley A Budgeon; Vincent Doré; Tenielle Porter; Pierrick Bourgeat; Rachel F Buckley; Kevin Murray; Kathryn A Ellis; Berwin A Turlach; Olivier Salvado; David Ames; Ralph N Martins; Dorene Rentz; Colin L Masters; Christopher C Rowe; Victor L Villemagne
Journal:  Neurobiol Aging       Date:  2020-06-10       Impact factor: 4.673

3.  Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.

Authors:  Suzanne E Schindler; Yan Li; Virginia D Buckles; Brian A Gordon; Tammie L S Benzinger; Guoqiao Wang; Dean Coble; William E Klunk; Anne M Fagan; David M Holtzman; Randall J Bateman; John C Morris; Chengjie Xiong
Journal:  Neurology       Date:  2021-09-09       Impact factor: 11.800

4.  Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals.

Authors:  Laura M van der Kall; Thanh Truong; Samantha C Burnham; Vincent Doré; Rachel S Mulligan; Svetlana Bozinovski; Fiona Lamb; Pierrick Bourgeat; Jurgen Fripp; Stephanie Schultz; Yen Y Lim; Simon M Laws; David Ames; Christopher Fowler; Stephanie R Rainey-Smith; Ralph N Martins; Olivier Salvado; Joanne Robertson; Paul Maruff; Colin L Masters; Victor L Villemagne; Christopher C Rowe
Journal:  Neurology       Date:  2020-11-12       Impact factor: 9.910

5.  Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.

Authors:  Alexis Moscoso; Michel J Grothe; Nicholas J Ashton; Thomas K Karikari; Juan Lantero Rodriguez; Anniina Snellman; Marc Suárez-Calvet; Henrik Zetterberg; Kaj Blennow; Michael Schöll
Journal:  Brain       Date:  2021-02-12       Impact factor: 13.501

6.  Concatenating plasma p-tau to Alzheimer's disease.

Authors:  Betty M Tijms; Charlotte E Teunissen
Journal:  Brain       Date:  2021-02-12       Impact factor: 13.501

7.  Predict Disease Progression With Reaction Rate Equation Modeling of Multimodal MRI and PET.

Authors:  Li Su; Yujing Huang; Yi Wang; James Rowe; John O'Brien
Journal:  Front Aging Neurosci       Date:  2018-10-08       Impact factor: 5.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.